State-of-the-art paradigm of corticosteroid therapy for immune-mediated inflammatory kidney diseases
- Authors: Bulanov N.M.1, Bobkova I.N.1, Moiseev S.V.1
-
Affiliations:
- Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 95, No 6 (2023)
- Pages: 451-456
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/133103
- DOI: https://doi.org/10.26442/00403660.2023.06.202265
- ID: 133103
Cite item
Full Text
Abstract
Since 1950’s corticosteroids (CS) have remained the cornerstone of immunosuppressive therapy for immune-mediated kidney diseases. However multiple adverse events, associated with the prolonged CS therapy, became the basis for the development of novel treatment approaches. Current evidence supports the implementation of the steroid-sparing regimens for the treatment of different types of glomerulonephritis. Randomised controlled trial PEXIVAS demonstrated the efficacy and safety of early steroid tapering, starting from the second week of therapy, in patients with ANCA-associated vasculitis with kidney involvement. Several trials showed the efficacy of oral prednisolone 0.3–0.5 mg/kg/daily as a part of multitarget therapy for severe proliferative lupus nephritis. A combination of calcineurin inhibitors and low-dose CS are effective for remission induction in membranous nephropathy, as well as the steroid-free rituximab regimen for the patients with moderate risk of disease progression. Medium dose CS showed promising effect in patients with IgA-nephropathy. Long-term high dose CS remain the standard-of-care for the treatment of minimal change disease and focal segmental glomerulosclerosis, however patients with steroid-dependent and relapsing disease tacrolimus and rituximab can help to achieve steroid-sparing effect. The role of CS pulse-therapy is currently debated, nevertheless it remains a compulsory treatment in several conditions. Thus, overall trend is directed towards the minimization of the maximal doses of CS and/or treatment duration. However, to implement this approach morphological verification of the diagnosis and personalized assessment of the potential risk and benefit are required.
Full Text
##article.viewOnOriginalSite##About the authors
Nikolay M. Bulanov
Sechenov First Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: bulanov_n_m@staff.sechenov.ru
ORCID iD: 0000-0002-3989-2590
канд. мед. наук, доц. каф. внутренних, профессиональных болезней и ревматологии Клиники ревматологии, нефрологии и профпатологии им. Е.М. Тареева Университетской клинической больницы №3
Russian Federation, MoscowIrina N. Bobkova
Sechenov First Moscow State Medical University (Sechenov University)
Email: bulanov_n_m@staff.sechenov.ru
ORCID iD: 0000-0002-8007-5680
д-р мед. наук, проф. каф. внутренних, профессиональных болезней и ревматологии Клиники ревматологии, нефрологии и профпатологии им. Е.М. Тареева Университетской клинической больницы №3
Russian Federation, MoscowSergey V. Moiseev
Sechenov First Moscow State Medical University (Sechenov University)
Email: bulanov_n_m@staff.sechenov.ru
ORCID iD: 0000-0002-7232-4640
чл.-кор. РАН, д-р мед. наук, проф., зав. каф. внутренних, профессиональных болезней и ревматологии, дир. Клиники ревматологии, нефрологии и профпатологии им. Е.М. Тареева Университетской клинической больницы №3
Russian Federation, MoscowReferences
- McCall MF, Ross A, Wolman B, et al. The nephrotic syndrome in children treated with ACTH and cortisone. Arch Dis Child. 1952;27(134):309-21.
- Barnett HL, McNamara H, McCrory W, et al. The effects of ACTH and cortisone on the nephrotic syndrome. AMA Am J Dis Child. 1950;80(3):519-20.
- Chaudhuri JN, Ghosal SP. Observations on prednisolone treated cases of nephrotic syndrome; a preliminary report. Indian J Pediatr. 1958;25(123):201-9.
- Fahey JL, Leonard E, Churg J, Godman G. Wegener’s granulomatosis. Am J Med. 1954;17(2):168-79.
- Thorn GW, Forsham PH, Frawley TF, et al. The clinical usefulness of ACTH and cortisone. N Engl J Med. 1950;242(21):824-34.
- Pollak VE, Pirani CL, Kark RM. Effect of large doses of prednisone on the renal lesions and life span of patients with lupus glomerulonephritis. J Lab Clin Med. 1961;57:495-511.
- Тареев Е.М., Насонова В.А. Место стероидных гормонов в комплексном лечении так называемых больших коллагенозов. Советская медицина. 1960;12:3-12 [Tareev EM, Nasonova VA. The place of steroid hormones in the complex treatment of the so called major collagenosis. Soviet Meidicine. 1960;12:3-12 (in Russian)].
- Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314(10):614-9.
- Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983;98(1):76-85.
- Wilson CB, Dixon FJ. Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int. 1973;3(2):74-89.
- Black DAK, Rose G, Brewer DB. Controlled trial of prednisone in adult patients with the nephrotic syndrome. Br Med J. 1970;3(5720):421.
- Mebrahtu TF, Morgan AW, Keeley A, et al. Dose dependency of iatrogenic glucocorticoid excess and adrenal insufficiency and mortality: a cohort study in England. J Clin Endocrinol Metab. 2019;104(9):3757-67. doi: 10.1210/jc.2019-00153
- Walsh M, Merkel P, Peh C, et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med. 2020;382(7):622-31. doi: 10.1056/NEJMoa1803537
- Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):S1-276. doi: 10.1016/j.kint.2021.05.021
- Буланов Н.М., Добронравов В.А., Захарова Е.В., и др. Поражение почек при АНЦА-ассоциированных васкулитах (АНЦА-ассоциированный гломерулонефрит). Ассоциация нефрологов России. Режим доступа: https://rusnephrology.org/wp-content/uploads/2021/02/ANCA.pdf. Ссылка активна на 09.03.2023 [Bulanov NM, Dobronravov VA, Zakharova EV, et al. Kidney damage in ANCA-associated vasculitis (ANCA-associated glomerulonephritis). Association of Nephrologists of Russia. Available at: https://rusnephrology.org/wp-content/uploads/2021/02/ANCA.pdf. Accessed: 09.03.2023 (in Russian)].
- Chanouzas D, McGregor JG, Poulton CJ, et al. Increase in adverse events with pulsed methylprednisolone used for induction of remission in severe anca associated vasculitis. Nephrol Dial Transplant. 2015;30(Suppl. 3):iii117-8. doi: 10.1093/ndt/gfv171.41
- Jayne DRW, Merkel PA, Schall TJ, Bekker P. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med. 2021;384(7):599-609. doi: 10.1056/NEJMoa2023386
- Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771-80. doi: 10.1056/NEJMoa1404231
- Smith RM, Jones RB, Specks U, et al. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis. 2020;79(9):1243-9. doi: 10.1136/annrheumdis-2019-216863
- Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. Arthritis Care Res (Hoboken). 2010;62(8):1166-73. doi: 10.1002/acr.20176
- Zeher M, Doria A, Lan J, et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus. 2011;20(14):1484-93. doi: 10.1177/0961203311418269
- Ruiz-Irastorza G, Danza A, Perales I, et al. Prednisone in lupus nephritis: how much is enough? Autoimmun Rev. 2014;13(2):206-14. doi: 10.1016/j.autrev.2013.10.013
- Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):S713-23. doi: 10.1136/annrheumdis-2020-216924
- Бобкова И.Н., Буланов Н.М., Ватазин А.В., и др. Диагностика и лечение волчаночного нефрита. Ассоциация нефрологов России. Режим доступа: https://rusnephrology.org/wp-content/uploads/2021/09/lupus.pdf. Ссылка активна на 09.03.2023 [Bobkoba IN, Bulanov NM, Vatazin AV, et al. Diagnosis and treatment of lupus nephritis. Association of Nephrologists of Russia. Available at: https://rusnephrology.org/wp-content/uploads/2021/09/lupus.pdf. Accessed: 09.03.2023 (in Russian)].
- Rovin BH, Solomons N, Pendergraft WF, et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019;95(1):219-31. doi: 10.1016/j.kint.2018.08.025
- Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013;72(8):1280-6. doi: 10.1136/annrheumdis-2012-202844
- Новиков П.И., Моисеев С.В. Глюкокортикостероиды при системной красной волчанке: перспективы стероидосберегающей терапии. Клиническая фармакология и терапия. 2022;31(4):18-27 [Novikov PI, Moiseev SV. Glucocorticoids in systemic lupus erythematosus: future of steroid-sparing therapy. Klinicheskaia farmakologiia i terapiia. 2022;31(4):18-27 (in Russian)]. doi: 10.32756/0869-5490-2022-4-18-27
- Ji L, Xie W, Zhang Z. Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual. Rheumatology (Oxford). 2021;60(12):5517-26. doi: 10.1093/rheumatology/keab149
- Mathian A, Pha M, Haroche J, et al. Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial. Ann Rheum Dis. 2020;79(3):339-46. doi: 10.1136/annrheumdis-2019-216303
- Ji L, Gao D, Hao Y, et al. Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal. Rheumatology (Oxford). 2022;62(1):181-9. doi: 10.1093/rheumatology/keac225
- Ji L, Xie W, Fasano S, Zhang Z. Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis. Lupus Sci Med. 2022;9(1):e000603. doi: 10.1136/lupus-2021-000603
- Van Den Brand JAJG, Ruggenenti P, Chianca A, et al. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. J Am Soc Nephrol. 2017;28(9):2729-37. doi: 10.1681/ASN.2016091022
- Qiu TT, Zhang C, Zhao HW, Zhou JW. Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: A systematic review and meta-analysis of 21 clinical trials. Autoimmun Rev. 2017;16(2):136-45. doi: 10.1016/j.autrev.2016.12.005
- Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med. 2019;381(1):36-46. doi: 10.1056/NEJMoa1814427
- Dahan K, Debiec H, Plaisier E, et al. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. J Am Soc Nephrol. 2017;28(1):348-58. doi: 10.1681/ASN.2016040449
- Fernández-Juárez G, Rojas-Rivera J, Logt AE van de, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2021;99(4):986-98. doi: 10.1016/j.kint.2020.10.014
- Scolari F, Delbarba E, Santoro D, et al. Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial. J Am Soc Nephrol. 2021;32(4):972-82. doi: 10.1681/ASN.2020071091
- Батюшин М.М., Бобкова И.Н., Боброва Л.А., и др. Мембранозная нефропатия. Ассоциация нефрологов России. Режим доступа: https://rusnephrology.org/wp-content/uploads/2021/09/membranous.pdf. Ссылка активна на 09.03.2023 [Batyushin MM, Bobkoba IN, Bobrova LA, et al. Membranous nephropathy. Association of Nephrologists of Russia. Available at: https://rusnephrology.org/wp-content/uploads/2021/09/membranous.pdf. Accessed: 09.03.2023 (in Russian)].
- Rauen T, Wied S, Fitzner C, et al. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020;98(4):1044-52. doi: 10.1016/j.kint.2020.04.046
- Rauen T, Eitner F, Fitzner C, et al. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med. 2015;373(23):2225-36. doi: 10.1056/NEJMoa1415463
- Manno C, Torres DD, Rossini M, et al. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009;24(12):3694-701. doi: 10.1093/ndt/gfp356
- Pozzi C, Bolasco PG, Fogazzi G, et al. Corticosteroids in IgA nephropathy: A randomised controlled trial. Lancet. 1999;353(9156):883-7. doi: 10.1016/s0140-6736(98)03563-6
- Lv J, Wong MG, Hladunewich MA, et al. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA. 2022;327(19):1888-98. doi: 10.1001/jama.2022.5368
- Батюшин М.М., Бобкова И.Н., Ватазин А.В., и др. Гломерулярные болезни: иммуноглобулин А-нефропатия. Ассоциация нефрологов России. Режим доступа: https://rusnephrology.org/wp-content/uploads/2021/04/iga_060421-1.pdf. Ссылка активна на 09.03.2023 [Batyushin MM, Bobkoba IN, Vatazin AV, et al. Glomerular diseases: immunoglobulin A-nephropathy. Association of Nephrologists of Russia. Available at: https://rusnephrology.org/wp-content/uploads/2021/04/iga_060421-1.pdf. Accessed: 09.03.2023 (in Russian)].
- Fellström BC, Barratt J, Cook H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017;389(10084):2117-27. doi: 10.1016/S0140-6736(17)30550-0
- Tam WK F, Tumlin J, Barratt J, et al. SUN-036 Spleen tyrosine kinase (SYK) inhibition in IgA nephropathy: a global, phase II, randomised placebo-controlled trial of fostamatinib. Kidney Int Rep. 2019;4(7):S168. doi: 10.1016/j.ekir.2019.05.431
- Lafayette RA, Rovin BH, Reich HN, et al. Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy. Kidney Int Rep. 2020;5(11):2032-41. doi: 10.1016/j.ekir.2020.08.003
- Бобкова И.Н., Ватазин А.В., Добронравов В.А., и др. Гломерулярные болезни: фокально-сегментарный гломерулосклероз. 2022. Ассоциация нефрологов России. Режим доступа: https://rusnephrology.org/wp-content/uploads/2021/04/fsgs.pdf. Ссылка активна на 09.03.2023 [Bobkova IN, Vatazin AV, Dobronravov VA, et al. Glomerular diseases: focal segmental glomerulosclerosis. 2022. Russian Association of Nephrologists. Available at: https://rusnephrology.org/wp-content/uploads/2021/04/fsgs.pdf. Accessed: 09.03.2023 (in Russian)].
- Medjeral-Thomas NR, Lawrence C, Condon M, et al. Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with De Novo Minimal Change Disease: A Multicenter, Randomized, Controlled Trial. Clin J Am Soc Nephrol. 2020;15(2):209-18. doi: 10.2215/CJN.06180519
- Li X, Liu Z, Wang L, et al. Tacrolimus Monotherapy after Intravenous Methylprednisolone in Adults with Minimal Change Nephrotic Syndrome. J Am Soc Nephrol. 2017;28(4):1286-95. doi: 10.1681/ASN.2016030342
- Duncan N, Dhaygude A, Owen J, et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant. 2004;19(12):3062-7. doi: 10.1093/ndt/gfh536
- Goumenos DS, Tsagalis G, El Nahas AM, et al. Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: a five-year follow-up study. Nephron Clin Pract. 2006;104(2):c75-82. DOI:1159/000093993
- Papakrivopoulou E, Shendi AM, Salama AD, et al. Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease. Nephrology (Carlton). 2016;21(10):893-900. doi: 10.1111/nep.12744
- Ren H, Lin L, Shen P, et al. Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis. Oncotarget. 2017;8(55):93438-43. doi: 10.18632/oncotarget.21833